Unlike previously validating the two higher-affinity GPC2 CARs19, the clone we chose had failed in targeting lower antigen density targets and we wanted to determine if it could achieve effective tumor targeting in DIPG given the high level of GPC2 detected in our proteomics. The gene discussed is GPC2; the disease is neoplasm.